You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GB20

Showing 1 - 25 of 1,704
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent DLBCL, Recurrent Follicular Lymphoma, Refractory DLBCL Trial in Seattle (Laboratory Biomarker Analysis, Pembrolizumab,

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jul 20, 2022

Advanced Hepatocellular Carcinoma Trial in Worldwide (Enzalutamide, Placebo)

Completed
Has Results
  • Advanced Hepatocellular Carcinoma
  • San Francisco, California
  • +37 more
Feb 18, 2022

Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma, Refractory Nodular

Not yet recruiting
  • Nodular Lymphocyte Predominant Hodgkin Lymphoma
  • +2 more
  • Biopsy
  • +9 more
  • (no location specified)
Jun 1, 2023

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Houston (Rituximab, Zanubrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,

Active, not recruiting
  • Prolymphocytic Leukemia
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Prostate Cancer Trial in Worldwide (enzalutamide, abiraterone acetate, prednisone)

Recruiting
  • Prostate Cancer
  • Anchorage, Alaska
  • +126 more
Aug 23, 2022

Global, Multicentre, Non Interventional Advagraf Conversion

Completed
  • Kidney Transplantation
  • Camperdown, New South Wales, Australia
  • +128 more
Nov 10, 2022

Recurrent DLBCL, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma Trial in Houston (other, drug,

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +3 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 26, 2022

CCND1 Positive, CCND2 Positive, CCND3 Positive Trial in Houston (drug, other, biological)

Active, not recruiting
  • CCND1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 11, 2022

Dry Eye Syndrome, Xerophthalmia Trial (Acupuncture, Oral microbiota, Schirmer's test)

Recruiting
  • Dry Eye Syndrome
  • Xerophthalmia
  • Acupuncture
  • +14 more
  • Taipei, Taiwan
    Ching-Mao Chang
Dec 11, 2022

Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1

Active, not recruiting
  • Ann Arbor Stage I Grade 1 Follicular Lymphoma
  • +3 more
  • Clinical Observation
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute

Recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Dec 16, 2022

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma Trial

Active, not recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 3, 2022

Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder Trial

Not yet recruiting
  • Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder
  • Polymorphic Post-Transplant Lymphoproliferative Disorder
  • Biopsy
  • +5 more
  • New Brunswick, New Jersey
  • +2 more
Mar 23, 2023

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric

Active, not recruiting
  • Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
  • +3 more
  • Phoenix, Arizona
  • +219 more
Aug 16, 2022

Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic

Active, not recruiting
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 2, 2022

Hematopoietic Cell Transplantation Recipient, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in

Active, not recruiting
  • Hematopoietic Cell Transplantation Recipient
  • +3 more
  • Allogeneic Bone Marrow Transplantation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022

Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann

Active, not recruiting
  • Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
  • +11 more
  • Washington, District of Columbia
  • +6 more
Feb 2, 2023

Recurrent DLBCL, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory DLBCL Trial in Houston (drug, procedure, other, biological)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

Low Back Pain Trial in Worldwide (Matching Placebo, Low Dose GRT6005, Medium Dose GRT6005)

Completed
  • Low Back Pain
  • Matching Placebo
  • +4 more
  • Senftenberg, Austria
  • +78 more
Jul 13, 2021

Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular

Recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • +19 more
  • CD47 Antagonist ALX148
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 9, 2022

CNS Lymphoma Trial in United States (drug, other, biological)

Active, not recruiting
  • Central Nervous System Lymphoma
  • Cincinnati, Ohio
  • +3 more
Sep 15, 2021

Recurrent DLBCL, Refractory DLBCL Trial in Sacramento (Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Chimeric Antigen Receptor T-Cell Therapy
  • +3 more
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Mar 8, 2022

Recurrent DLBCL, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory DLBCL Trial in United States (drug, other, biological)

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +5 more
  • Duarte, California
  • +3 more
Nov 17, 2022